MarcAlanSimonMDMS, FACP

Cardiology • San Francisco, CA

Heart Failure & Transplantation

Professor, Medicine, UCSF

Join to view full profile

Dr. Simon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Simon's full profile

Already have an account?

Office
535 Mission Bay Blvd S
San Francisco, CA 94143
Phone+1 415-353-3109

Fax+1 415-353-2528

Education & Training

UPMC Medical EducationFellowship, Advanced Heart Failure and Transplant Cardiology, 2004 - 2005
UPMC Medical EducationFellowship, Cardiovascular Disease, 2001 - 2004
University of ColoradoResidency, Internal Medicine, 1998 - 2001
University of Maryland School of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 2021 - 2025
PA State Medical License 1988 - 2022
CO State Medical License 2000 - 2003
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Inhaled Nitrite in Subjects With Pulmonary Hypertension Start of enrollment: 2012 Jun 01
Completed
Phase 2
A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System Start of enrollment: 2012 Dec 01
Terminated
Phase 3
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. Start of enrollment: 2014 Feb 14
Completed
Phase 3
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension Start of enrollment: 2017 Apr 01
Completed
Phase 1
Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction Start of enrollment: 2017 Oct 30
Completed
Phase 2
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH Start of enrollment: 2018 Jul 15
Terminated
Phase 2
Metformin for Pulmonary Hypertension HFpEF Start of enrollment: 2019 Feb 26
Recruiting
Phase 2
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 Start of enrollment: 2019 Apr 10
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

42 citations
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial.
Daniel Burkhoff, Barry A. Borlaug, Sanjiv J. Shah, Ronald Zolty, Ryan J. Tedford
JACC. Heart Failure. 2021-04-07
17 citations
Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction.
Andrea R. Levine, Marc A. Simon, Mark T. Gladwin
Trends in Cardiovascular Medicine. 2019-05-01
63 citations
Characterization of right ventricular remodeling in pulmonary hypertension associated with patient outcomes by 3-dimensional wall motion tracking echocardiography.
Keiko Ryo, Akiko Goda, Tetsuari Onishi, Antonia Delgado-Montero, Bhupendar Tayal
Circulation. Cardiovascular Imaging. 2015-06-01

Abstracts/Posters

[Board 482] Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009 Nab-Sirolimus an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
Marc Simon, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/17/2019

Grant Support

A Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection FractionNIAPresent

Professional Memberships

American College of Cardiology - ACC
Fellow
American Heart Association - AHA
Member